AbCellera Results Presentation Deck

Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 EMPOWER NEXT-GEN ANTI-CD3 ANTIBODIES FOR ONCOLOGY Large and growing market opportunity in the use of bispecifics specifically for T cell redirection in oncology through CD3 receptor engagement on T cells. O CD3+ T Cell O Target Cell

View entire presentation